What is Immunome's debt-to-equity?

Immunome (IMNM) reported debt-to-equity of 0× in Q1 2026.

How has Immunome's debt-to-equity changed year-over-year?

Immunome's debt-to-equity decreased by 59.4% year-over-year, from 0× to 0×.

What is the long-term trend for Immunome's debt-to-equity?

Over 4 years (2020 to 2025), Immunome's debt-to-equity has grown at a -15.7% compound annual growth rate (CAGR), from 0× to 0×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Immunome IMNM Debt-to-equity

Debt-to-equity at other companies

PfizerPFE

0.7×0.0×

Arcus BiosciencesRCUS

0.2×+0.1×

Nuvation BioNUVB

0.2×+0.2×

SELLAS Life Sciences Group, Inc.SLS

0×0.0×

IDEAYA Biosciences, Inc.IDYA

0×0.0×

Summit TherapeuticsSMMT

0×0.0×

Other financials

Income statement

See full

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

See full

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

See full

Market cap$2.19B+323%

Enterprise value$1.61B+470%

P/S545.2×+498×

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Current ratio21.7×+11.2×

Where this comes from

Calculated from Immunome’s reported figures.

total debt/total stockholders equity=0×

Based on the most recent quarter.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's debt-to-equity?: Immunome (IMNM) reported debt-to-equity of 0× in Q1 2026.
How has Immunome's debt-to-equity changed year-over-year?: Immunome's debt-to-equity decreased by 59.4% year-over-year, from 0× to 0×.
What is the long-term trend for Immunome's debt-to-equity?: Over 4 years (2020 to 2025), Immunome's debt-to-equity has grown at a -15.7% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-equity mean?: Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.